{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:38:16Z","timestamp":1787985496918,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.survophthal.2020.12.002","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T17:07:16Z","timestamp":1608138436000},"page":"572-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-1345","authenticated-orcid":false,"given":"Prem","family":"Nichani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamiar","family":"Mireskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin N.","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.survophthal.2020.12.002_bib1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41433-018-0151-y","article-title":"Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes","volume":"32","author":"Adams","year":"2018","journal-title":"Eye"},{"issue":"10","key":"10.1016\/j.survophthal.2020.12.002_bib2","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.survophthal.2020.12.002_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.survophthal.2020.12.002_bib5","doi-asserted-by":"crossref","first-page":"f170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"10.1016\/j.survophthal.2020.12.002_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2008.09.035","article-title":"Astigmatism in the early treatment for retinopathy of prematurity study: findings to 3 years of age","volume":"116","author":"Davitt","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2020.12.002_bib7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2020.12.002_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ophtha.2018.12.012","article-title":"Laser treatment for retinopathy of prematurity: a decade since ETROP","volume":"126","author":"Emami","year":"2019","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2020.12.002_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2020.12.002_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2020.12.002_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2020.12.002_bib12","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0","year":"2011"},{"key":"10.1016\/j.survophthal.2020.12.002_bib13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/bjo.82.11.1265","article-title":"Ophthalmological long-term follow up of preterm infants: a population based, prospective study of the refraction and its development","volume":"82","author":"Holmstrom","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2020.12.002_bib14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib15","first-page":"140","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J\u00a0AAPOS"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcjo.2018.05.005","article-title":"Increased incidence of retinopathy of prematurity and evolving treatment modalities at a Canadian tertiary centre","volume":"54","author":"Isaza","year":"2019","journal-title":"Can J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2020.12.002_bib17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabatas","year":"2017","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.survophthal.2020.12.002_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3341\/kjo.2019.0011","article-title":"Refractive outcomes of 4-year-old children after intravitreal anti-vascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity","volume":"33","author":"Kang","year":"2019","journal-title":"Korean J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2020.12.002_bib19","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.12.002_bib20","first-page":"61","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.survophthal.2020.12.002_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.12.002_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12886-018-0973-1","article-title":"The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units","volume":"18","author":"Leng","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2020.12.002_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-620X.106103","article-title":"Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity","volume":"5","author":"Lin","year":"2012","journal-title":"Oman J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2020.12.002_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.oftal.2016.12.007","article-title":"Anatomical and refractive outcomes in patients with treated retinopathy of prematurity","volume":"92","author":"Lolas","year":"2017","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.12.002_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-019-1067-4","article-title":"Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study","volume":"19","author":"Lyu","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2020.12.002_bib27","first-page":"454","article-title":"Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity","volume":"10","author":"McLoone","year":"2006","journal-title":"J\u00a0AAPOS"},{"issue":"7","key":"10.1016\/j.survophthal.2020.12.002_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.survophthal.2020.12.002_bib29","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"Moran","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib30","first-page":"128","article-title":"Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study","volume":"22","author":"Morrison","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.survophthal.2020.12.002_bib31","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.12659\/MSM.897095","article-title":"Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis","volume":"22","author":"Nicoara","year":"2016","journal-title":"Med Sci Monit"},{"issue":"6","key":"10.1016\/j.survophthal.2020.12.002_bib32","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A\u00a0systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.survophthal.2020.12.002_bib33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and myopia in the Early Treatment for Retinopathy Prematurity study: findings to 3 years of age","volume":"115","author":"Quinn","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib34","first-page":"124","article-title":"Progression of myopia and myopia in the Early Treatment for Retinopathy Prematurity study: findings at 4 to 6 years of age","volume":"17","author":"Quinn","year":"2013","journal-title":"J\u00a0AAPOS"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0161-6420(00)00527-3","article-title":"Does cryotherapy affect refractive error? Results from treated versus control eyes in the Cryotherapy for Retinopathy of Prematurity trial","volume":"108","author":"Quinn","year":"2001","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2020.12.002_bib36","first-page":"61","article-title":"Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity","volume":"31","author":"Roohipoor","year":"2019","journal-title":"J\u00a0Curr Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.12.002_bib37","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjo.86.9.1035","article-title":"Emmetropisation following preterm birth","volume":"86","author":"Saunders","year":"2002","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2020.12.002_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/aje\/kwm189","article-title":"Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles","volume":"166","author":"Shrier","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"10208","key":"10.1016\/j.survophthal.2020.12.002_bib39","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.survophthal.2020.12.002_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00417-016-3443-6","article-title":"Treatment for stage 4A retinopathy of prematurity: laser and\/or ranibizumab","volume":"255","author":"Sukgen","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2020.12.002_bib41","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1111\/aos.13069","article-title":"The German ROP Registry: data from 90 infants treated for retinopathy of prematurity","volume":"94","author":"Walz","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2020.12.002_bib42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/bjophthalmol-2011-300015","article-title":"Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city, Mexico","volume":"95","author":"Zepeda-Romero","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2020.12.002_bib43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2020.12.002_bib46","author":"Wells"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625720301739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625720301739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:50:11Z","timestamp":1758541811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625720301739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0039625720301739"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2020.12.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2020.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}